Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation

Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation: A Prospective, Multicenter Cohort Study

By establishing a prospective, multicenter lung transplantation clinical cohort, this study aims to systematically evaluate the utility of cfDNA fragmentomics, peripheral blood single-cell sequencing, and proteomics in monitoring and predicting graft dysfunction after lung transplantation, and to develop a multi-omics predictive model for early identification, dynamic monitoring, and mechanistic investigation of acute lung allograft dysfunction (ALAD) and chronic lung allograft dysfunction (CLAD).

Study Overview

• Status: Recruiting
• Conditions: Lung Diseases
• Intervention / Treatment: Other: longitudinal changes in multi-omics profiling of peripheral blood

Detailed Description

ALAD predominantly occurs in the early post-transplant period. This project aims to establish a systematic framework for monitoring and predicting post-lung transplant dysfunction, with a specific focus on acute lung allograft dysfunction (ALAD) and its progression to chronic lung allograft dysfunction (CLAD). We plan to conduct a prospective, multicenter clinical cohort study, longitudinally collecting peripheral blood and bronchoalveolar lavage fluid (BALF) samples from transplant recipients at various time points. By integrating multi-omics technologies-including cfDNA fragmentomics, peripheral blood single-cell sequencing, and proteomic mass spectrometry-with pulmonary function (FEV1) and clinicopathological data, we seek to delineate the dynamic landscape of post-lung transplant dysfunction. Compared to previous studies that relied on single indicators or one-time measurements, this project is distinguished by several key features: Firstly, the use of cfDNA fragmentomic characteristics to infer tissue origin, enabling highly specific detection of graft injury without requiring donor genotype information. Secondly, the integration of single-cell transcriptomics to comprehensively analyze the dynamics of peripheral immune cell subsets, providing a basis for early immunological warning of dysfunction. Thirdly, the application of proteomics to reveal expression levels, post-translational modifications, and protein-protein interactions in plasma samples. Fourthly, the construction of a multi-dimensional integrated model incorporating blood, BALF, and pulmonary function data, with the goal of establishing a generalizable early warning system. Through this research, we aim not only to enhance the early identification and intervention of ALAD but also to lay the foundation for elucidating the molecular mechanisms underlying CLAD development and exploring potential therapeutic targets.

• Study Type: Observational
• Enrollment (Estimated): 244

Contacts and Locations

• Study Contact: Name: Junqi Wu; Phone Number: +8615618977421; Email: wujunqi@tongji.edu.cn

Study Locations

• China
  • Shanghai, China
    • Recruiting
    • Shanghai Pulmonary Hospital
    • Contact: Junqi Wu; Phone Number: +8615618977421; Email: wujunqi@tongji.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Recipients undergoing single or double lung transplantation

Description

Inclusion Criteria:

1. Recipients aged ≥18 years undergoing single or double lung transplantation;
2. Postoperative recipients capable of understanding and providing written informed consent, and willing to comply with scheduled follow-ups and sample collections as required by the study;
3. Postoperative recipients clinically assessed as stable and eligible for routine follow-up and hematological examinations;
4. Recipients able to undergo dynamic pulmonary function monitoring during follow-up;
5. No planned participation in other interventional trials during the study period that may impact immune function or pulmonary function;
6. Retransplant patients will be considered as a new transplant event and may be included in the analysis.

Exclusion Criteria:

1. History of active malignancy or presence of untreated malignancy within 5 years prior to transplantation;
2. Presence of active systemic infection or significant immune rejection;
3. Female patients who are pregnant or lactating;
4. Any other condition deemed by the investigator to be inappropriate for inclusion .

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of ALAD	through study completion, an average of 1 year

Collaborators and Investigators

• Sponsor: Chang Chen
• Investigators: Principal Investigator: Chang Chen, MD,PHD, Shanghai Pulmonary Hospital, Shanghai, China

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2025
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): March 1, 2030

Study Registration Dates

• First Submitted: November 17, 2025
• First Submitted That Met QC Criteria: November 21, 2025
• First Posted (Actual): November 24, 2025

Study Record Updates

• Last Update Posted (Actual): November 24, 2025
• Last Update Submitted That Met QC Criteria: November 21, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases
• Other Study ID Numbers: L25-802

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No